Skip to main content
SpringerLink
Log in
Book cover

Transfusionsmedizin und Immunhämatologie pp 343–359Cite as

Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand- Syndrom

  • Chapter

  • 6614 Accesses

Zusammenfassung

Die häufigsten angeborenen hämorrhagischen Diathesen sind Störungen der plasmatischen Gerinnung. Ursachen sind

  • die quantitative Verminderung eines oder mehrerer Gerinnungsfaktoren,

  • verminderte oder fehlende Aktivierbarkeit eines oder mehrerer Gerinnungsfaktoren aufgrund eines qualitativen Defekts,

  • die Präsenz eines Inhibitors, der ihre Aktivierung blockiert.

Die häufigsten Störungen sind die Hämophilie A und B und das von-Willebrand-Syndrom. Selten sind vererbte Mangelzustände der Gerinnungsfaktoren I, II, V, VII, X, XI, XII und XIII. Eine kausale Therapie ist bisher beim Menschen nicht möglich. Das quantitative Ausmaß der Defekte bestimmt die Blutungsneigung, wobei die hämostatische Mindestaktivität für jeden einzelnen Gerinnungsfaktor unterschiedlich ist.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  1. Aledort LM and the International Study Group (1992/93) Orthopedic outcome study. Vorgetragen auf den Sitzungen des SSC der ISTH, München 1992 und New York 1993

    Google Scholar 

  2. Allain J-P (1976) Dosage requirements for substitution therapy in hemophiliacs; general principles. Scand H Haematol 1090; 24 (Suppl 35):29–32

    Google Scholar 

  3. Allain JP, Frommel D (1976) Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 47:973–982

    PubMed  CAS  Google Scholar 

  4. Anson DS, Choo KH, Rees DJG, et al. (1984) The gene structure of human antihaemophilic factor IX. EMBO J 3:1053–1060

    PubMed  CAS  Google Scholar 

  5. Antonarakis SE, Rossiter JP, Young, et al. (1995) Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 86:2206–2212

    PubMed  CAS  Google Scholar 

  6. Astermark J, Berntorp E, White GC, et al. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7:267–272

    Article  PubMed  CAS  Google Scholar 

  7. Astermark J, Oldenburg J, Pavlova A, et al. (2006) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with haemophilia A. Blood 107:3167–3172

    Article  PubMed  CAS  Google Scholar 

  8. Astermark J, Oldenburg J, Carlson J, et al. (2006) Polymorphisms in the TNFA gene and the risk of inhibitor development in patiennts with haemophilia A. Blood 108:3739–3745

    Article  PubMed  CAS  Google Scholar 

  9. Astermark J, Wang X, Oldenburg J (2007) Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe haemophilia A. J Thromb Haemost 5:263–265

    Article  PubMed  CAS  Google Scholar 

  10. Bardin JM, Sultan Y (1990) Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion 30:441–443

    Article  PubMed  CAS  Google Scholar 

  11. Berkowitz SD, Ruggeri ZM (1994) The management of von Willebrand Disease. Biomed Prog 7:5–10

    Google Scholar 

  12. Berntorp E (1994) Die Auswirkungen einer Subsitutionstherapie auf das Immunsystem von Blutern. Hämostaseologie 14:74–80

    Google Scholar 

  13. Brackmann H-H (1984) Induced immunotolerance in factor VIII inhibitor patients. In: Hoyer LD (ed) Factor VIII inhibitors. Liss, New York, pp 181–195

    Google Scholar 

  14. Brackmann HH, Lenk H, Scharrer J, et al. (1999) German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 5:203–206

    Article  PubMed  CAS  Google Scholar 

  15. Brettler DB, Levine PH (1994) Clinical Manifestations and therapy of inherited coagulation factor deficiencies. In: Colman RW, Hirsh J, Marder VJ, Salzmann EW (eds) Hemostasis and thrombosis, 3rd edn. Lippincott, Philadelphia, pp 169–183

    Google Scholar 

  16. Chalmers EA, Brown SA, Keeling D, et al. (2007) Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 13:149–155

    Article  PubMed  CAS  Google Scholar 

  17. Collins P, Budde U, Rand JH, et al. (2008) Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 14:49–55

    Article  PubMed  Google Scholar 

  18. Collins PW, Mathias M, Hanley J, et al. (2009) Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 7:787–794

    Article  PubMed  CAS  Google Scholar 

  19. Delannoy A, Saillez AC (1988) High-dose intravenous gamma globulin for acquired vWd. Br J Haematol 70:387

    Article  PubMed  CAS  Google Scholar 

  20. Dimichelle DM, Hoots WK, Pipe SW, et al. (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia 13:1–22

    Article  CAS  Google Scholar 

  21. European Study Group of Factor VIII Antibody (1979) Development of factor VIII antibody in haemophilic monocygotic twins. Scand J Haematol 23:64–68

    Google Scholar 

  22. Ewing NP, Sanders NL, Dietrich SL, et al. (1988) Induction of immune tolerance to factor VIII in hemophiliac with inhibitors. JAMA 259:65–68

    Article  PubMed  CAS  Google Scholar 

  23. Gawryl MS, Hoyer LW (1982) Inactivation of factor VIII procoagulant activity by two different types of human antibodies. Blood 60:1103

    PubMed  CAS  Google Scholar 

  24. Gitschier J, Wood WI, Goralka TM, et al. (1984) Characterization of the human factor VIII gene. Nature (London) 312:326

    Article  CAS  Google Scholar 

  25. Goldsmith JC and the Recombinante Study Group (1991) Clinical trial of Recombinate: safety and efficacy of a genetically engineered antihemophilic factor in previously treated patients. Blood 78 (Suppl 1):64a

    Google Scholar 

  26. Goudemand J, Rothschild C, Demiguel V, et al. (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 107:46–51

    Article  PubMed  CAS  Google Scholar 

  27. Gouw SC, van den Berg HM, le CS, et al. (2007) Treatment characteristics and the risk of inhibitor develoment: a multi-center cohort study among previously untretaed patients with severe haemophilia A. J Thromb Haemost 5:1383–1390

    Article  PubMed  CAS  Google Scholar 

  28. Gouw SC, van der Bom JG, van den Berg M, et al. (2007) Treatmentrelated risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 109:4648–4654

    Article  PubMed  CAS  Google Scholar 

  29. Gralnick HR (1991) Von Willebrand’s Disease. In: Ratnoff OD, Forbes ChD (eds) Disorders of Hemostasis. Saunders, Philadelphia, pp 203–244

    Google Scholar 

  30. Hedner U (2003) Recombinant factor VII a (Novo Seven) as a hemostatic agent. Dis Mon 49:39–48

    PubMed  Google Scholar 

  31. Hellmann L, Smedsröd B, Sandberg H, Pettersson U (1989) Secretion of coagulant factor VIII activity and antigen by in vitro cultivated rat liver sinusoidal endothelial cells. Br J Haematol 73:348–355

    Article  Google Scholar 

  32. Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briët E, Van der Eb AJ (1993) Toward gene therapy for Hemophilia A: long-term persistence of factor VIII-Secreting Fibroblasts after transplantation into immunodeficient mice. Human gene therapy 4:179–186

    Article  PubMed  CAS  Google Scholar 

  33. Hunault M, Bauer KA (2000) Recombinant factor VII a for the treatment of congenital factor VII deficiency. Semin Thromb Hemost 26:401–405

    Article  PubMed  CAS  Google Scholar 

  34. Jaffe EA, Hoyer LW, Nachmann RL (1974) Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 71:1906–1909

    Article  PubMed  CAS  Google Scholar 

  35. Kernoff PBA, Thomas ND, Lilley PA, Matthews KB, Goldmann E, Tuddenham GD (1984) Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 63:31

    PubMed  CAS  Google Scholar 

  36. Kiesewetter H, Spannagl M (2009) Prokoagulatoren. In: Bundesärztekammer (Hrsg) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. Aufl. Deutscher Ärzte-Verlag, S 131–167

    Google Scholar 

  37. Köhler M, Hellstern P, Miyashita C, et al. (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemostas 55:108–111

    Google Scholar 

  38. Köhler M, Seifried E, Hellstern P, Pindur G, Leipnitz G, Mörsdorf S, Fasco F, Wenzel E (1988) In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients – the influence of reagents and standards. Blut 57:341–345

    Article  PubMed  Google Scholar 

  39. Köhler M, Hellstern P, Tarrasch H, et al. (1989) Subcutaneous injection of esmopressin (DDAVP): Evaluation of a new, more concentrated preparation. Haemostasis 1:38–44

    Google Scholar 

  40. Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B (1994) Haemate P® in Children with von Willebrand’s Disease. Haemostasis 1994:304– 310

    Google Scholar 

  41. Kreuz W, Becker S, Lenz E, et al. (1995) Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance of factor VIII. Sem Thromb Hemost 21:382–389

    Article  CAS  Google Scholar 

  42. Kreuz W, Auerswald G, Ehrenforth S, et al. (1996) Immuntoleranz bei Kindern mit Hemmkörperhämophilie. In: Scharrer J, Schramm W (Hrsg) 25. Hämophilie-Symposium 1994. Springer, Berlin Heidelberg New York, S 67–80

    Chapter  Google Scholar 

  43. Landbeck G (1987) HIV-Infektion, AIDS-Manifestation und Todesursachen Hämophiler der Bundesrepublik Deutschland. Elipse 1987:156

    Google Scholar 

  44. Lechner K, Fasching I, Niessner H, Novotny C (1983) Current situation of home care in Austria. In: Abe T (ed) Proc 3rd Int Symp H T. Kyoritsu Printings, Tokyo, p 105

    Google Scholar 

  45. Lethagen S, Ragnarson-Tennvall G (1993) Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect of bleeding symptoms and socio-economic factors. Ann Hematol 66:257–260

    Article  PubMed  CAS  Google Scholar 

  46. Lethagen S, Harris AS, Sjörin E, Nilsson IM (1987) Intranasal and intravenous administration of desmopressin. Effect of VIII/vWF, pharmacokinetics and reproducibility. Thrombos Haemostas 58:1033–1036

    CAS  Google Scholar 

  47. Liu H-W, Ofosu FA, Chang PL (1993) Expression of Human IX by microencapsulated recombinant fibroblasts. Human Gene Ther 4:291–301

    Article  CAS  Google Scholar 

  48. Logan LJ (1992) Treatment of von Willebrand’s Disease. In: Penne JA, Hassouna HJ (eds) Hematology/oncology clinics in North America, coagulation disorders I. Saunders, Philadelphia, pp 1079–1094

    Google Scholar 

  49. Lusher Ju (2002) First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Sem Thromb Hemost 28:273–276

    Article  CAS  Google Scholar 

  50. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate Previously Untreated Patients Study Group (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy and development of inhibitors. N Engl J Med 328:453–459

    Article  PubMed  CAS  Google Scholar 

  51. Mannucci PM (1993) Clinical evaluation of viral safety coagulation factor VIII and IX concentrates. Vox Sang 64:197–203

    Article  PubMed  CAS  Google Scholar 

  52. Mannucci PM (1995) Risk of inhibitor development after intermediate purity coagulation factor concentrates: Is it truly low? Thrombos Haemost 74:997

    CAS  Google Scholar 

  53. Mannucci PM, Lusher JM (1989) Desmopressin and thrombosis. Lancet II:675–676

    Article  Google Scholar 

  54. Mannucci PM, Lombardi R, Bader R, et al. (1984) Studies of the pathophysiology of acquired vWD in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 64:614

    PubMed  CAS  Google Scholar 

  55. Martinowitz U, Luboshitz J, Bashari D, et al. (2009) Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia A. Haemophilia 15:676–685

    Article  PubMed  CAS  Google Scholar 

  56. Mauser-Bunschoten EP, Nilsson IM, Kasper CK (1991) Immune tolerance, a 1990 approach: In: Lusher JM, Kessler CM (eds) Hemophilia and Kapitel 25 • Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand-Syndrom von Willebrand’s Disease in the 1960s. Elsevier, Amsterdam New York, pp 265–269

    Google Scholar 

  57. McMillan CW, Shaprio SS, Whitehurst D, et al. (1988) The natural history of factor VIII : C inhibitors in patients with hemophilia A. A national cooperative study. II Observations on the initial development of factor VIII: C inhibitors. Blood 71:344

    PubMed  CAS  Google Scholar 

  58. Michiels JJ, Budde U, van der Planken M, et al. (2001) Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Clin Haematol 14:401–436

    CAS  Google Scholar 

  59. Miesbach W (2008) Laboratory diagnosis and clinical manifestations of patients with dysfibrinogenemia. J Lab Med 32:401–405

    Google Scholar 

  60. Miesbach W, Galanakis D, Scharrer I (2009) Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis 20:366–370

    Article  PubMed  CAS  Google Scholar 

  61. Montgomery RR, Coller BS (1994) Von Willebrand Disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis. Lippincott, Philadelphia, pp 134–168

    Google Scholar 

  62. Niessner H (1988) von-Willebrand-Syndrom. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York, S 392–403

    Google Scholar 

  63. Nilsson IM (1991) Prophylactic treatment of severe haemophilia in Sweden. R Soc Med Serv, Round Table Ser 25: Factor VIII: purity and prophylaxis, pp 36–40

    Google Scholar 

  64. Nilsson IM, et al. (1994) Hemophilia, Pharmacia Plasma Products (Hrsg Fa. Pharmacia)

    Google Scholar 

  65. Oldenburg J (2001) Mutation profiling in haemophilia A. Thromb Haemost 85:577–579

    PubMed  CAS  Google Scholar 

  66. Oldenburg J, Schwaab R (2001) Molecular biology of coagulation factors. Semin Thromb Hemost 27:313–324

    Article  PubMed  CAS  Google Scholar 

  67. Oldenburg J, Brackmann HH, Schwaab R (2000) Risk factors for inhibitor development in haemophilia A. Haematologica 85:7–14

    PubMed  CAS  Google Scholar 

  68. Pabinger I, Lechner K (1988) Therapie mit plasmatischen Gerinnungsfaktoren. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York, S 373–381

    Google Scholar 

  69. Pittmann D, Millenson M, Marquette K, et al. (1992) A2 domain of human recombinant-derived F VIII is required for procoagulant activity but not for thrombin cleavage. Blood 79:389–397

    Google Scholar 

  70. Rosendaal FR, Veltkamp I, Smit C, et al. (1989) Mortality and causes of death in Dutch haemophiliacs, 1973–86. Br J Haematol 71:71–76

    Article  PubMed  CAS  Google Scholar 

  71. Rosendaal FR, Smit C, Briet E (1991) Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 62:5–15

    Article  PubMed  CAS  Google Scholar 

  72. Ruggeri ZM, Ware J (1993) Von Willebrand factor. FASEB J 7:308–316

    PubMed  CAS  Google Scholar 

  73. Scharrer I (1994) Rekombinante Faktor-VIII-Konzentrate. Hämostaseologie 14:69–73

    Google Scholar 

  74. Scharrer I, Vigh T, Aygören-Pürsün E (1994) Experience with haemate P in von Willebrand’s disease in adults. Haemostasis 298–303

    Google Scholar 

  75. Schimpf K (1976) Factor VIII dosis in prophylaxis of hemophilia A; a further controlled study. In: Proc 11th Congr World Fed Hemophilia, Kyoto, vol 8. Academia (Tokyo) 8:363–366

    Google Scholar 

  76. Schimpf K (1986) Liver disease in haemophilia. Lancet I:323 u. 572

    Google Scholar 

  77. Schimpf K (1994) Therapie der Hämophilien. Hämostaseologie 14:44–54

    Google Scholar 

  78. Schramm W (1983–1993) Chronologie zu Hämophilie und AIDS, Hamburger Hämophilie-Symposien 1983–1993

    Google Scholar 

  79. Schramm W (1993) Experience with prophylaxis in Germany. Seminars Hematol 30 (Suppl 2):12–15

    CAS  Google Scholar 

  80. Schramm W (1994) Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland. Hämostaseologie 1994:81–83

    Google Scholar 

  81. Schramm W (1995) Sustitutionstherapie bei thrombophilen und hämophilen Diathesen. Hämostaseologie 15:210–214

    Google Scholar 

  82. Schramm W, Krebs H (2003) HIV infection and causes of death in patients with hemophilia in Germany (Year 2000/2001 Survey). 32nd Hemophilia Symposium Hamburg 2001. Springer, Berlin Heidelberg, pp 3–12

    Book  Google Scholar 

  83. Schramm W, Oldenburg J (2009) Faktor-VIII-Konzentrate, Faktor-VIII-/von Willebrand-Faktor-Konzentrate, Faktor IX-Konzentrate, aktivierte Prothrombinkomplex-Konzentrate. In: Bundesärztekammer (Hrsg) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. Aufl. Deutscher Ärzte-Verlag, S 111–130

    Google Scholar 

  84. Schramm W, Scharrer I (2000) Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland. GTH-Hämophiliekommission, Update 1999. Hämophilieblätter 34:62–65

    Google Scholar 

  85. Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Sem Thromb Hemost 1:336

    Google Scholar 

  86. Shelton Inloes BB, Mannucci PM, Federici AB, Sadler JE (1987) Gene deletions correlate with the development of alloantibodies in VWD. J Clin Invest 79:1459

    Article  PubMed  CAS  Google Scholar 

  87. Silberstein LE, Abrahm J, Shattil SJ (1987) The efficacy of intensive plasma exchange in acquired vWd. Transfusion 27:234

    Article  PubMed  CAS  Google Scholar 

  88. Smith MP, Spence KJ, Waters El, et al. (1999) Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 81:35–38

    PubMed  CAS  Google Scholar 

  89. Sporn LA, Chavin SI, Marder VJ, Wagner DD (1985) Biosynthesis of on Willebrand protein by human megakaryocytes. J Clin Invest 76:1102–1106

    Article  PubMed  CAS  Google Scholar 

  90. Sultan Y (1995) High pun’ty factor VIII concentrates for the treatment of HIV-positive patients with haemophilia. Blood Coagul Fibrinolysis 6 (Suppl 1):80–81

    Article  Google Scholar 

  91. Tedder RS, Briggs M, Ring C, et al. (1991) Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 79:512–515

    Article  PubMed  CAS  Google Scholar 

  92. Uehlinger J, Rose E, Aledort LM, Lemer R (1989) Successful treatment of an acquired vWf antibody by extracorporeal immunoadsorption. N Engl J Med 320:254

    Article  PubMed  CAS  Google Scholar 

  93. Varon D, Martinowitz U (1998) Continuous infusion therapy in haemophilia. Haemophilia 4:431–435

    Article  PubMed  CAS  Google Scholar 

  94. von Auer C, Oldenburg J, von Depka M (2005) Inhibitor development in patients with haemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 1051:498–505

    Article  Google Scholar 

  95. von Willebrand EA (1926) Finska Lakaresallsb Handl 68:87–112

    Google Scholar 

  96. Wion KI, Kelly D, Summerfield JA, et al. (1985) Distribution of factor VIII mRNa and antigen in human liver and other tissues. Nature (London) 317:726–729

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Transfusionsmedizin u. Immunhämatologie;, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main DRK-Blutspendedienst Baden- Württemberg - Hessen gemeinnützige GmbH, Sandhofstr. 1, 60528, Frankfurt/Main

    Prof. Dr. med. Dr. h.c. E. Seifried

  2. Institut für Transfusionsmedizin u. Immunhämatologie;, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main DRK-Blutspendedienst Baden-Württemberg - Hessen gemeinnützige GmbH, Sandhofstr. 1, 60528, Frankfurt am Main

    Dr. M. M. Müller

  3. Medizinische Klinik III - Hämophilieambulanz, Johann-Wolfgang-Goethe-Universitätsklinik Frankfurt Haus 31, Theordor-Stern-Kai 7, 60590, Frankfurt

    Dr. W. Miesbach

  4. Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn

    Prof. Dr. J. Oldenburg

Authors
  1. Prof. Dr. med. Dr. h.c. E. Seifried
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. M. M. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. W. Miesbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. J. Oldenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Transfusionsmedizin, Universitätsklinikum Rostock AöR, Ernst-Heydemann-Str. 6, 18057, Rostock

    Volker Kiefel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Seifried, E., Müller, M., Miesbach, W., Oldenburg, J. (2010). Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand- Syndrom. In: Kiefel, V., Mueller-Eckhardt, C. (eds) Transfusionsmedizin und Immunhämatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12765-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12765-6_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12764-9

  • Online ISBN: 978-3-642-12765-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation